Bayer decides to withdraw cholesterol lowering drugBMJ 2001; 323 doi: https://doi.org/10.1136/bmj.323.7309.359/a (Published 18 August 2001) Cite this as: BMJ 2001;323:359
- Fred Charatan
Cerivastatin (Baycol in the United States, Lipobay in the United Kingdom), a cholesterol lowering drug made by Bayer Corporation and initially approved in the US in 1997, has been withdrawn by the manufacturer. There have been 31 deaths in the US from severe rhabdomyolysis in patients taking the drug. Twelve patients were taking concomitant gemfibrozil, which lowers blood concentration of triglycerides.
Rhabdomyolysis, a serious and potentially fatal adverse effect of …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial